Nuwiq added around surgery for people with hemophilia A
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This Phase 4 study looks at how well Nuwiq works to manage bleeding risk around the time of major elective surgery in people with severe hemophilia A who already take emicizumab to prevent bleeds. It may help your surgical team plan safer blood-clotting support during and after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe hemophilia A (very low factor VIII activity, under 1% based on your history)
- You are male and at least 12 years old
- You have used factor VIII medicine (any FVIII product) for at least 150 days before screening
- You have been on regular emicizumab prevention for at least 1 month before a planned major elective surgery
- You can give consent (or your parent/legal guardian can, if you are a minor)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new longer-lasting factor VIII medicine (FRSW107) for on-demand treatment of bleeding episodes. It is for males with severe hemophilia A who have been previously treated at least 150 times.
This trial tests a new long-acting factor VIII treatment (FRSW107) for people with severe hemophilia A. It aims to prevent bleeding episodes with fewer injections, and you must have already used factor VIII treatments many times before.
This trial tests a new long-acting factor VIII treatment (FRSW107) for boys under 12 with severe hemophilia A. It aims to see if the drug is safe and effective at preventing or treating bleeding episodes.
This trial tests a new form of factor VIII that lasts longer in the body, so you may need fewer infusions. It is for men with severe hemophilia A who have already used factor VIII products for at least 150 days.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This trial studies how to dose Nuwiq (a factor medicine) and track outcomes in girls and women with hemophilia A who need major surgery. It may help confirm the best way to manage bleeding risk around surgery.
Hear when a new Severe Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.